The B Hub
Resource Library
Welcome to our Resource Library Blog page, where you can discover valuable content tailored to your specific interests and needs. Whether you're seeking information on the latest advancements in hemophilia B treatment or looking for personal stories from individuals with hemophilia B, this is the place to be. With our convenient filter options or by exploring the dedicated hubs, you can easily access articles that resonate with you on a deeper level. Take advantage of this resource and empower yourself with knowledge and insights that are relevant to your unique journey.
European Medicines Agency (EMA) Begins Review of EtranaDez, a Gene Therapy Treatment for Hemophilia B
The Coalition for Hemophilia B is excited to report that on March 28, 2022, CSL Behring announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for their drug etranacogene dezaparvovec (EtranaDez) EtranaDez is an investigational adeno-associated virus five (AAV5)-based gene therapy administered as a one-time treatment for people with hemophilia B patients with a severe bleeding phenotype. If approved, it will provide people living with hemophilia B in the European Union (EU) and European Economic Area (EEA) with their first-ever gene therapy treatment option. The review will take place under accelerated assessment which will potentially reduce the timeline for approval.